A phase I study of daily treatment with a ceramide-dominant triple lipid mixture commencing in neonates - Test2 - elhamkhani - TriplyDB

A phase I study of daily treatment with a ceramide-dominant triple lipid mixture commencing in neonates

A phase I study of daily treatment with a ceramide-dominant triple lipid mixture commencing in neonates

http://www.wikidata.org/entity/Q34218186

about

The infant skin barrier: can we preserve, protect, and enhance the barrier?Barrier repair therapy in atopic dermatitis: an overview.Atopic dermatitis and the atopic march revisited.Cohort Profile: Melbourne Atopy Cohort study (MACS).Increased risk of peanut allergy in infants of Asian-born parents compared to those of Australian-born parents.ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study.

P2860

Q28275320-C9832EBC-D8AD-441B-93BE-2CC19D7B0711 Q38113741-5B7D77E0-8676-4C87-B2F4-FCC44A164FD8 Q38151826-4CB964AD-B4DA-4A72-98C4-CBEC08865B6D Q40706266-DB3A0A0A-067A-4289-B55E-0A1600733CA7 Q44827639-7871AB8E-6195-4D91-81EE-BE671F08A8A8 Q47849230-B0A926EE-36B8-47D8-B13B-E1CF47B79829 Q48238458-92443207-4094-4A06-A32D-5466CF3F3DCF

P2860

A phase I study of daily treatment with a ceramide-dominant triple lipid mixture commencing in neonates

http://www.wikidata.org/entity/Q34218186

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

A phase I study of daily treat ...... mixture commencing in neonates

@ast

A phase I study of daily treat ...... mixture commencing in neonates

@en

A phase I study of daily treat ...... mixture commencing in neonates

@nl

type

label

A phase I study of daily treat ...... mixture commencing in neonates

@ast

A phase I study of daily treat ...... mixture commencing in neonates

@en

A phase I study of daily treat ...... mixture commencing in neonates

@nl

prefLabel

A phase I study of daily treat ...... mixture commencing in neonates

@ast

A phase I study of daily treat ...... mixture commencing in neonates

@en

A phase I study of daily treat ...... mixture commencing in neonates

@nl

P1433

Q34218186-665DF173-1DD9-472A-9BD3-58AE6E3E06F1

P1476

Q34218186-01535644-072A-43AA-8102-D49127A999E4

P2093

Q34218186-0F0A8103-32F9-47B6-9F76-8433A38EEAD9

Q34218186-7BF8BF1C-B09C-44C7-A295-97828F630BED

Q34218186-BE53BD83-13E5-4E23-9F41-0841109C5F3C

Q34218186-CFD6301E-6689-4BE5-B3A9-9ECDAA922483

P2860

Q34218186-0B1D371E-00B2-45D2-8180-7B3835871EA1

Q34218186-11DF7390-A1C1-4D4D-BA05-A6DB67C5A415

Q34218186-2B3E41F5-FAA5-44DA-AE4F-DD9057768E68

Q34218186-2F731621-A816-4EC2-B290-3E6CD5743C9B

Q34218186-38D451F3-3A62-4E4B-A228-0A5CCC96DCB5

Q34218186-3A0F4E8A-4191-4433-BD39-98CD0A7007F4

Q34218186-6B0F36B4-2CA2-47E4-8417-2A773971F160

Q34218186-761E0AC0-F94D-4EF1-9D27-DA810B3B10DC

Q34218186-887CFA4E-C8A8-437F-B089-6DBBEFBB4586

Q34218186-B89BE75E-3D64-4DEC-A576-32112014A0C5

P2888

Q34218186-8F848227-B071-468A-A58B-5E4E1D3FF05C

P304

Q34218186-66598238-7AB2-4719-BD24-643A6AA2675F

P31

Q34218186-4EC4D466-B532-40B7-A20A-DF2B8F162E86

P356

Q34218186-7778ED42-D221-4BE4-B8F8-F7960401C65C

P478

Q34218186-E3B8B5A6-F108-4D35-B8A5-C883FFEE9BFF

P50

Q34218186-1E6BD7F8-C159-4162-8DBA-6E35DF1D7816

Q34218186-270C66BC-01C2-437A-82A3-3D183FDB758F

Q34218186-48EBE5DE-E341-4235-BD06-FCC10D7173EF

Q34218186-72348812-E066-4C8D-9D04-E940E9BEDF80

Q34218186-9D695D61-CEB9-4C7E-950D-E6DE223210F4

Q34218186-F2B8F89A-1567-418D-BC30-02A5E8943CDE

P577

Q34218186-A7CFC72B-D48B-43CF-B13C-C406974154A9

P5875

Q34218186-B7AD34A1-F901-4164-A68D-219EAA7CEC9D

P698

Q34218186-23FF8DDC-23A5-40E2-B19E-A166A37A42F4

P932

Q34218186-E4E72F63-2F40-4ECB-BB61-6F464F60B971

P356

P1433

BMC Dermatology

P1476

A phase I study of daily treat ...... mixture commencing in neonates

@en

P2093

Colin F Robertson

http://www.w3.org/2001/XMLSchema#string

Della Forster

http://www.w3.org/2001/XMLSchema#string

George Varigos

http://www.w3.org/2001/XMLSchema#string

Mimi Lk Tang

http://www.w3.org/2001/XMLSchema#string

P2860

Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma

Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis

Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis.

The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation.

A pilot study of emollient therapy for the primary prevention of atopic dermatitis

Atopic dermatitis and the atopic march.

On the effects of topical synthetic pseudoceramides: comparison of possible keratinocyte toxicities provoked by the pseudoceramides, PC104 and BIO391, and natural ceramides

Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms

Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis.

An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial.

P2888

P304

3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-5945-12-3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Shyamali C. Dharmage

Michael J. Abramson

P577

2012-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223983837

http://www.w3.org/2001/XMLSchema#string

P698

22471265

http://www.w3.org/2001/XMLSchema#string

P932

3368745

http://www.w3.org/2001/XMLSchema#string